Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix Q1 net income rises to $29.6 million; 2026 Adjusted EBITDA outlook reaffirmed

Positive Impact 3 of 5 earnings Written later

Pediatrix Medical Group reported first-quarter 2026 results, with net revenue of $476.2 million, up from $458.4 million a year earlier, and net income of $29.6 million, or $0.36 per diluted share, compared with $0.24 in the prior-year quarter. The company reaffirmed its full-year 2026 Adjusted EBITDA range of $280 million to $300 million, which gives shareholders a continued outlook for the year.

Key points

  • Q1 2026 Adjusted EBITDA was $58.2 million, compared with $49.2 million in Q1 2025.
  • Adjusted EPS was $0.44, compared with $0.33 in the prior-year quarter.
  • Same-unit volume-driven revenue decreased 1.6 percent, while reimbursement-related factors increased same-unit revenue by 4.4 percent.
  • Full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million was reaffirmed; cash and equivalents were $205.8 million at March 31, 2026.

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECMay 5, 2026, 6:50 AM ET
Accession number0001193125-26-204982

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.